Where I see patients (1)
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.
CDKN2A/B co-deletion is associated with increased risk of local and distant intracranial recurrence after surgical resection of brain metastases.
Identification of risk factors associated with leptomeningeal disease after resection of brain metastases.
Journal of neurosurgery
- Request appointment
- Refer a patient
- (415) 353-2966